下載本文檔
版權(quán)說明:本文檔由用戶提供并上傳,收益歸屬內(nèi)容提供方,若內(nèi)容存在侵權(quán),請(qǐng)進(jìn)行舉報(bào)或認(rèn)領(lǐng)
文檔簡(jiǎn)介
1、Hotline: 400-820-3792Inhibitors Agonists Screening Librarieswww.MedChemEPLX8394Cat. No.: HY-18972CAS No.: 1393466-87-9分式: CHFNOS分量: 542.53作靶點(diǎn): Raf作通路: MAPK/ERK Pathway儲(chǔ)存式: Powder -20C 3 years4C 2 yearsIn solvent -80C 6 months-20C 1 month溶解性數(shù)據(jù)體外實(shí)驗(yàn) DMSO : 39 mg/mL (71.89 mM)H2O : 40% PEG300 5% Tween-8
2、0 45% salineSolubility: 2.08 mg/mL (3.83 mM); Clear solutionBIOLOGICAL ACTIVITY1/3 Master of Small Molecules 您邊的抑制劑師www.MedChemE物活性 PLX8394種有效的,選擇性的 BRaf 抑制劑,抑制 BRAFV600E 活性的 IC50 值約為 5 nM。IC50 & Target BRafV600E5 nM (IC50)體外研究 PLX8394 potently inhibits phosphorylation of ERK1/2 in PRT #3 and PRT #4
3、 cells at 25 nM and in additionto parental cells at 10 nM. PLX8394 effectively reduces cyclin D3 and cyclin D1, phosphorylation ofretinoblastoma protein, and expression of cyclin A2 in parental cells and PRT #3 and PRT #4 cells. PLX8394inhibits ERK1/2 phosphorylation and the growth of vemurafenib-re
4、sistant cells harboring either a BRAFV600K/L505H double mutation or an transposon-induced, N-terminal truncated form of BRAF 1. PLX8394significantly impairs tumor cell growth and suppresses MAPK signaling in LA cell lines expressing eitherendogenous V600E or non-V600 mutant forms of BRAF 2.體內(nèi)研究 PLX8
5、394 (150 mg/kg/d) substantially suppresses tumor growth, MAPK pathway signaling and tumor cellproliferation in these H1755 xenograft tumors without overt toxicity in mice. PLX8394 combines with erlotinibyields plasma erlotinib concentrations of 1 M 2.PROTOCOLCell Assay 1 For MTT assays, 2103 cells a
6、re seeded in triplicate in 96 wells in their regular culture medium (containingPLX4720 for PRT lines). Next day, cells are washed twice with PBS and then the medium is replenishedcontaining the indicated RAF inhibitor. Medium is changed 48 hours later and after a further 48 hours, 10 Lof 5 mg/mL MTT
7、 reagent is added to wells, and incubated for three hours. Formazan crystals are thensolubilized overnight with a 1:10 dilution of 0.1 M glycine (pH 10.5) in DMSO. Wells are then analyzed at 450nM in a Multiskan Spectrum spectrophotometer. Results depicted are normalized to DMSO conditions andare a
8、composite of three independent experiments. Error bars shown are representative of the standard errorof mean (SEM).MCE has not independently confirmed the accuracy of these methods. They are for reference only.Animal H1755 tumor xenografts are generated by injection of 5106 cells in a 50/50 mixture
9、for matrigel and PBSAdministration 2 into 6- to 8-wk-old female NOD/SCID mice. Mice are randomized to treatment groups once tumors reach anaverage size of 150 mm3. H1755 cells are s.c. implanted and allowed to grow to appr 200 mm3 (4 wk afterimplantation). Mice are then treated with vehicle, vemuraf
10、enib, or PLX8394 for 15 d. The vehicle for daily oralgavage is PEG 400 20% (vol/vol), tocopheryl polyethylene glycol succinate (TPGS) 5% (vol/vol), water75% (vol/vol). PLX8394 is dissolved in PEG 400 20% (vol/vol), TPGS 5% (vol/vol), and water 75%(vol/vol) and vortexed continuously throughout the do
11、sing period. PLX8394 is given daily by oral gavage at adose of 150 mg/kg/d.MCE has not independently confirmed the accuracy of these methods. They are for reference only.戶使本產(chǎn)品發(fā)表的科研獻(xiàn) Cancer Discov. 2018 Sep;8(9):1130-1141. Nat Commun. 2018 Nov 14;9(1):4775.2/3 Master of Small Molecules 您邊的抑制劑師www.Med
12、ChemE Clin Sci (Lond). 2019 Apr 16;133(8):919-932. Mol Cell Biol. 2016 Sep 26;36(20):2612-25.See more customer validations on HYPERLINK / www.MedChemEREFERENCES1. Basile KJ, et al. Inhibition of mutant BRAF splice variant signaling by next-generation, selective RAF inhibitors. Pigment Cell MelanomaRes. 2014 May;27(3):479-484.2. Okimoto RA, et al. Preclinical efficacy of a RAF inhibitor that evades paradoxical MAPK pathway activation in protein kinase BRAF-mutant lung cancer. Proc Natl Acad Sci U S A. 2016 Nov 22;113(47):13456-13461McePdfHeig
溫馨提示
- 1. 本站所有資源如無特殊說明,都需要本地電腦安裝OFFICE2007和PDF閱讀器。圖紙軟件為CAD,CAXA,PROE,UG,SolidWorks等.壓縮文件請(qǐng)下載最新的WinRAR軟件解壓。
- 2. 本站的文檔不包含任何第三方提供的附件圖紙等,如果需要附件,請(qǐng)聯(lián)系上傳者。文件的所有權(quán)益歸上傳用戶所有。
- 3. 本站RAR壓縮包中若帶圖紙,網(wǎng)頁(yè)內(nèi)容里面會(huì)有圖紙預(yù)覽,若沒有圖紙預(yù)覽就沒有圖紙。
- 4. 未經(jīng)權(quán)益所有人同意不得將文件中的內(nèi)容挪作商業(yè)或盈利用途。
- 5. 人人文庫(kù)網(wǎng)僅提供信息存儲(chǔ)空間,僅對(duì)用戶上傳內(nèi)容的表現(xiàn)方式做保護(hù)處理,對(duì)用戶上傳分享的文檔內(nèi)容本身不做任何修改或編輯,并不能對(duì)任何下載內(nèi)容負(fù)責(zé)。
- 6. 下載文件中如有侵權(quán)或不適當(dāng)內(nèi)容,請(qǐng)與我們聯(lián)系,我們立即糾正。
- 7. 本站不保證下載資源的準(zhǔn)確性、安全性和完整性, 同時(shí)也不承擔(dān)用戶因使用這些下載資源對(duì)自己和他人造成任何形式的傷害或損失。
最新文檔
- 中文教育書籍出版行業(yè)投資機(jī)會(huì)與風(fēng)險(xiǎn)識(shí)別及應(yīng)對(duì)策略報(bào)告
- 納米食品科學(xué)行業(yè)消費(fèi)者群體特征分析
- 精準(zhǔn)農(nóng)業(yè)保險(xiǎn)行業(yè)發(fā)展方向及匹配能力建設(shè)研究報(bào)告
- 社交游戲行業(yè)發(fā)展現(xiàn)狀及潛力分析研究報(bào)告
- 多元文化電影行業(yè)五年發(fā)展洞察報(bào)告
- 多肽功能食品科技行業(yè)相關(guān)項(xiàng)目經(jīng)營(yíng)管理報(bào)告
- 在線健身教育行業(yè)研究報(bào)告
- 基因治療行業(yè)投資機(jī)會(huì)分析與策略研究報(bào)告
- 《 行政事業(yè)單位內(nèi)部控制制度體系研究與完善》范文
- 2023年雅安市名山中學(xué)考核招聘教師考試試題及答案
- 社會(huì)工作者作文(通用6篇)
- 2020AHA心肺復(fù)蘇指南(成人基礎(chǔ)及高級(jí)生命支持)
- 遼寧阜新煤化工基地產(chǎn)業(yè)發(fā)展規(guī)劃
- 牛屠宰加工工藝流程圖及工藝說明及牛肉凍品分割標(biāo)準(zhǔn)
- 學(xué)院意識(shí)形態(tài)工作責(zé)任制實(shí)施細(xì)則
- 芬太尼透皮貼劑的護(hù)理
- 簡(jiǎn)易烤三文魚做法
- 自考高級(jí)英語(yǔ)(課程代碼00600)上下冊(cè)中英翻譯整理及歷年考試真題
- 上海百匯醫(yī)院新建項(xiàng)目 施工組織設(shè)計(jì)方案
- 2023年全國(guó)初中數(shù)學(xué)聯(lián)合數(shù)學(xué)競(jìng)賽試題及答案版本
- 人教版八年級(jí)上冊(cè)數(shù)學(xué)《直角三角形全等判定》賽課一等獎(jiǎng)教學(xué)創(chuàng)新課件
評(píng)論
0/150
提交評(píng)論